全部 标题 作者
关键词 摘要

OALib Journal期刊
ISSN: 2333-9721
费用：99美元
投递稿件

为什么选择我们？ >>
- 开源期刊
- 同行审议
- 快速出刊
- 终身存储
- 免费检索
- 免费推广
- 更多...
- 搜索引擎

Lung Cancer: Targets and Therapy

ISSN Print: 1179-2728

ISSN Online:

主页: https://www.dovepress.com/lung-cancer-targets--therapy-journal

分享:




Go

Targeted inhibition in tumors with ALK dependency

Kwak EL, Clark JW, Shaw AT

Targeted inhibition in tumors with ALK dependency

Kwak EL,Clark JW,Shaw AT

Anaplastic lymphoma kinase (ALK) inhibitors for second-line therapy of non-small cell lung cancer

Berghmans T, Remmelink M, Awada A

Economic evaluation of pemetrexed versus erlotinib as second-line treatment of patients with advanced/metastatic non-small cell lung cancer in Greece: a cost minimization analysis

Fragoulakis VF, Pallis AG, Kaitelidou DK, Maniadakis NM, Georgoulias VG

Non-small cell lung cancer: the era of targeted therapy

Antonoff MB, D'Cunha J

Update on biomarkers for the detection of lung cancer

Jantus-Lewintre E, Usó M, Sanmartín E, Camps C

MET targeted therapy for lung cancer: clinical development and future directions

Feng Y, Ma PC

A pilot study of a metronomic chemotherapy regimen with weekly low-dose docetaxel for previously treated non-small cell lung cancer

Yokoi T, Tamaki T, Shimizu T, Nomura S

Lung cancer in women

Barrera-Rodriguez R, Morales-Fuentes J

Association of p21 Ser31Arg and p53 Arg72Pro polymorphisms with lung cancer risk in CAPUA study

Souto-García A, Fernández-Somoano A, Pascual T, álvarez-Avellón SM, Tardón A

Single nucleotide polymorphisms as susceptibility, prognostic, and therapeutic markers of nonsmall cell lung cancer

Zienolddiny S, Skaug V

Economic evaluation of pemetrexed versus erlotinib as second-line treatment of patients with advanced/metastatic non-small cell lung cancer in Greece: a cost minimization analysis

Fragoulakis VF,Pallis AG,Kaitelidou DK,Maniadakis NM

Lung cancer in women

Barrera-Rodriguez R,Morales-Fuentes J

Non-small cell lung cancer: the era of targeted therapy

Antonoff MB,D'Cunha J

A pilot study of a metronomic chemotherapy regimen with weekly low-dose docetaxel for previously treated non-small cell lung cancer

Yokoi T,Tamaki T,Shimizu T,Nomura S

Update on biomarkers for the detection of lung cancer

Jantus-Lewintre E,Usó M,Sanmartín E,Camps C

Association of p21 Ser31Arg and p53 Arg72Pro polymorphisms with lung cancer risk in CAPUA study

Souto-García A,Fernández-Somoano A,Pascual T,Álvarez-Avellón SM

MET targeted therapy for lung cancer: clinical development and future directions

Feng Y,Ma PC

Anaplastic lymphoma kinase (ALK) inhibitors for second-line therapy of non-small cell lung cancer

Berghmans T,Remmelink M,Awada A

Effectiveness of maintenance treatments for nonsmall cell lung cancer

Eadens MJ, Robinson SI, Price KA

Afatinib treatment in advanced non-small cell lung cancer

Hurwitz JL, Scullin P, Campbell L

Nimotuzumab, a novel monoclonal antibody to the epidermal growth factor receptor, in the treatment of non-small cell lung cancer

Takeda M, Okamoto I, Nishimura Y, Nakagawa K

Experience with carboplatin and etoposide maintenance chemotherapy in patients with extensive stage small cell lung cancer

Siddiqi A, Bahrain H, Auerbach M

Efficacy and safety of erlotinib in the treatment of metastatic non-small-cell lung cancer

Serena Ricciardi, Silverio Tomao, Filippo de Marinis

Emerging treatment options in the management of non-small cell lung cancer

Filosso PL, Sandri A, Oliaro A, Filippi AR, Cassinis MC, Ricardi U, Lausi P, Asioli S, Ruffini E

Emerging treatment options in the management of non-small cell lung cancer

Filosso PL,Sandri A,Oliaro A,Filippi AR

Effectiveness of maintenance treatments for nonsmall cell lung cancer

Eadens MJ,Robinson SI,Price KA

Afatinib treatment in advanced non-small cell lung cancer

Hurwitz JL,Scullin P,Campbell L

Single nucleotide polymorphisms as susceptibility, prognostic, and therapeutic markers of nonsmall cell lung cancer

Zienolddiny S,Skaug V

Nimotuzumab, a novel monoclonal antibody to the epidermal growth factor receptor, in the treatment of non-small cell lung cancer

Takeda M,Okamoto I,Nishimura Y,Nakagawa K

Circulating tumor cells (CTCs) in lung cancer: current status and future perspectives

Fumihiro Tanaka, Kazue Yoneda, Seiki Hasegawa

Drug resistance in lung cancer

Manish Shanker, David Willcutts, Jack A Roth, et al

Shifting the paradigm for maintenance therapy in advanced non-small-cell lung cancer

Barbara Melosky

Docetaxel in the treatment of non-small cell lung carcinoma: an update and analysis

Matthew A Gubens, Heather A Wakelee

Astragalus-containing Chinese herbal combinations for advanced non-small-cell lung cancer: a meta-analysis of 65 clinical trials enrolling 4751 patients

Jean Jacques Dugoua, Ping Wu, Dugald Seely, et al

Standing the test of time in Europe? Gefitinib in the treatment of non-small-cell lung cancer

Caroline Wilson, Sarah J Danson

The role of maintenance pemetrexed in the treatment of non-small-cell lung cancer

Saeed Rafii, Michael H Cullen

Azacitidine and decitabine have different mechanisms of action in non-small cell lung cancer cell lines

Aaron N Nguyen, Paul W Hollenbach, Normand Richard, et al

Dyspnea in lung cancer patients: a systematic review

Ganesan Kathiresan, Reynold F Clement, Meera T Sankaranarayanan

Genome-wide gene expression analysis of chemoresistant pulmonary carcinoid cells

Ulrike Olszewski, Robert Zeillinger, Klaus Geissler, et al

Maintenance therapy for metastatic non-small-cell lung cancer – the role of pemetrexed

Youval Katz, Robert A Somer

Refining the treatment of advanced nonsmall cell lung cancer

Shin Ogita, Antoinette J Wozniak

Go




©2008-2020 OALib, Inc | Public user content licensed CC-BY 4.0 unless otherwise specified. OALib ISSN Online: 2333-9721 OALib ISSN Print: 2333-9705